Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies-Reference-Cited by-同舟云学术

Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies

Published:2023-02-07 Issue:4 Volume:40 Page:1546-1559
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Barratt Jonathan^ORCID,Dellanna Frank,Portoles Jose,Choukroun Gabriel,De Nicola Luca,Young James,Dimković Nada,Reusch Michael

Funder

Astellas Pharma, Inc.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-023-02433-0.pdf

Reference32 articles.

1. Wingard RL, Chan KE, Lazarus JM, Hakim RM. The “right” of passage: surviving the first year of dialysis. Clin J Am Soc Nephrol. 2009;4(Suppl 1):S114–20.

2. Provenzano R, Shutov E, Eremeeva L, et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrol Dial Transplant. 2021;36:1717–30.

3. Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton). 2007;12:321–30.

4. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–90.

5. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–32.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances and clinical applications of red blood cell lifespan measurement;Heliyon;2024-09

2. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease;Biomedicines;2024-08-18

3. Pharmacological Regulation Possibilities of HIF for Its’ Mediated Pathologies in Clinical Practice;Annals of the Russian academy of medical sciences;2024-08-15

4. Consensus commentary and position of the Italian Society of Nephrology on KDIGO controversies conference on novel anemia therapies in chronic kidney disease;Journal of Nephrology;2024-05-06

5. A novel scenario in the therapeutic management of anemia of chronic kidney disease: placement and use of roxadustat;Journal of Nephrology;2024-01-08